Compare · HUM vs VRDN
HUM vs VRDN
Side-by-side comparison of Humana Inc. (HUM) and Viridian Therapeutics Inc. (VRDN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUM and VRDN operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $29.67B, about 16.9x VRDN ($1.75B).
- Over the past year, HUM is up 2.6% and VRDN is up 30.0% - VRDN leads by 27.4 points.
- HUM has been more active in the news (21 items in the past 4 weeks vs 15 for VRDN).
- Both have 25 recent analyst ratings on file.
- Company
- Humana Inc.
- Viridian Therapeutics Inc.
- Price
- -
- -
- Market cap
- $29.67B
- $1.75B
- 1M return
- +31.67%
- +7.90%
- 1Y return
- +2.60%
- +29.95%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 21
- 15
- Recent ratings
- 25
- 25
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Viridian Therapeutics Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Latest HUM
- Chief Financial Officer Mellet Celeste gave a grant of 15,387 units of Humana Common, decreasing direct ownership by 28% to 39,637 units (SEC Form 4)
- Chief Information Officer Mehta Japan was granted 9,448 units of Humana Common, increasing direct ownership by 122% to 17,176 units (SEC Form 4)
- President, Enterprise Growth Dintenfass David was granted 11,273 units of Humana Common, increasing direct ownership by 80% to 25,407 units (SEC Form 4)
- President & CEO Rechtin James A. was granted 35,633 units of Humana Common (SEC Form 4)
- Chief Human Resources Officer O'Hara Michelle A. was granted 10,485 units of Humana Common, increasing direct ownership by 110% to 20,026 units (SEC Form 4)
- Director Field Robert Stuart was granted 852 units of Humana Common (SEC Form 4)
- Chief Legal Officer Ventura Joseph C was granted 10,318 units of Humana Common, increasing direct ownership by 60% to 27,405 units (SEC Form 4)
- President, CenterWell Shetty Sanjay K was granted 9,945 units of Humana Common, increasing direct ownership by 82% to 22,088 units (SEC Form 4)
- President, Medicare Advantage Martin Aaron was granted 8,206 units of Humana Common, increasing direct ownership by 48% to 25,237 units (SEC Form 4)
- Florida Seniors Face High Rates of Poor Mental Health -- A Looming Crisis as State Braces for Aging Population Boom
Latest VRDN
- SEC Form FWP filed by Viridian Therapeutics Inc.
- SEC Form FWP filed by Viridian Therapeutics Inc.
- SEC Form 305B2 filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
- SEC Form 424B5 filed by Viridian Therapeutics Inc.
- SEC Form 424B5 filed by Viridian Therapeutics Inc.
- SEC Form FWP filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
- Viridian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form 10-Q filed by Viridian Therapeutics Inc.